,Gene,Gene synonym,Ensembl,Gene description,Chromosome,Position,Protein class,Evidence,Antibody,Reliability (IH),Reliability (Mouse Brain),Reliability (IF),Subcellular location,Prognostic p-value,RNA cancer category,RNA tissue category,RNA TS,RNA TS TPM,TPM max in non-specific,RNA cell line category,RNA CS,RNA CS TPM
0,ABAT,GABAT,ENSG00000183044,4-aminobutyrate aminotransferase,16,8674565-8784575,"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA041528, HPA041690",Enhanced,Supported,Supported,Mitochondria,"Renal cancer:5.44e-8 (favourable), Liver cancer:5.36e-5 (favourable), Lung cancer:5.93e-4 (favourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 164.5;kidney: 135.3;liver: 175.2,thyroid gland: 47.5,Cell line enhanced,,Hep G2: 83.0;MCF7: 60.0;RH-30: 64.1;T-47d: 39.1
1,ABCC6,"ARA, EST349056, MLP1, MRP6, PXE, URG7",ENSG00000091262,ATP binding cassette subfamily C member 6,16,16148928-16223522,"Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,HPA038105,,,Supported,Plasma membrane,Liver cancer:3.82e-4 (favourable),Tissue enhanced,Tissue enhanced,,kidney: 16.9;liver: 23.4,duodenum: 13.0,Cell line enriched,6.0,Hep G2: 45.5
2,AC009014.3,,ENSG00000271824,,5,136191468-136193134,Predicted membrane proteins,Evidence at transcript level,,,,,,"Liver cancer:1.63e-4 (favourable), Pancreatic cancer:6.13e-4 (favourable)",Tissue enhanced,Tissue enhanced,,duodenum: 13.2;kidney: 22.7,small intestine: 6.8,Cell line enhanced,,SCLC-21H: 2.0
3,ACOT4,"FLJ31235, PTE-Ib, PTE2B",ENSG00000177465,Acyl-CoA thioesterase 4,14,73591706-73596496,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA000779,Enhanced,,,,"Renal cancer:8.43e-5 (favourable), Pancreatic cancer:1.77e-4 (unfavourable)",Expressed in all,Tissue enhanced,,kidney: 8.9,liver: 4.9,Cell line enhanced,,CAPAN-2: 9.1;SK-BR-3: 12.3;T-47d: 38.6
4,ACOT6,C14orf42,ENSG00000205669,Acyl-CoA thioesterase 6,14,73610945-73619888,Predicted intracellular proteins,Evidence at protein level,HPA058258,Uncertain,,,,,Not detected,Tissue enhanced,,kidney: 3.8,adipose tissue: 1.7,Cell line enriched,7.0,T-47d: 9.6
5,ACSF2,"ACSMW, FLJ20920",ENSG00000167107,Acyl-CoA synthetase family member 2,17,50426158-50474845,"Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA024693,Enhanced,,Approved,Nucleoplasm<br>Microtubules<br>Cytosol,"Renal cancer:2.17e-4 (unfavourable), Urothelial cancer:2.41e-4 (favourable)",Expressed in all,Tissue enhanced,,kidney: 136.9,thyroid gland: 68.6,Expressed in all,,
6,ACY3,"ACY-3, HCBP1, MGC9740",ENSG00000132744,Aminoacylase 3,11,67642555-67650659,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA039219, HPA048187",Enhanced,,,,Endometrial cancer:4.80e-4 (favourable),Mixed,Tissue enhanced,,duodenum: 80.6;kidney: 53.3;small intestine: 78.6,"cervix, uterine: 16.1",Cell line enhanced,,CACO-2: 8.4;CAPAN-2: 13.6;Daudi: 41.2
7,ADGRF1,"GPR110, hGPCR36, PGR19",ENSG00000153292,Adhesion G protein-coupled receptor F1,6,46997703-47042363,"G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA038438,Approved,,,,Renal cancer:1.35e-5 (favourable),Mixed,Tissue enhanced,,esophagus: 14.6;kidney: 17.6;urinary bladder: 18.9,gallbladder: 9.4,Group enriched,9.0,A-431: 27.0;CAPAN-2: 99.3;HaCaT: 22.4;PC-3: 33.9;RPTEC TERT1: 38.6;RT4: 104.1
8,AGMAT,FLJ23384,ENSG00000116771,Agmatinase,1,15572353-15585110,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA026443, HPA028321",Enhanced,,,,Renal cancer:5.13e-4 (favourable),Group enriched,Tissue enhanced,,kidney: 158.9,liver: 36.6,Cell line enhanced,,CACO-2: 35.2;Hep G2: 70.8
9,AIF1L,"C9orf58, FLJ12783, IBA2",ENSG00000126878,Allograft inflammatory factor 1 like,9,131096476-131123152,Predicted intracellular proteins,Evidence at protein level,"HPA020522, HPA056852",Enhanced,,,,Renal cancer:5.54e-6 (favourable),Expressed in all,Tissue enhanced,,kidney: 287.5;spleen: 288.1,thyroid gland: 155.2,Cell line enhanced,,AF22: 139.6;NTERA-2: 106.7;RPTEC TERT1: 230.5
10,AK4,"AK3, AK3L1",ENSG00000162433,Adenylate kinase 4,1,65147549-65232145,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA042753, HPA049461",Enhanced,,Supported,Mitochondria,"Pancreatic cancer:4.34e-5 (unfavourable), Cervical cancer:4.17e-4 (unfavourable), Renal cancer:4.36e-4 (unfavourable), Stomach cancer:4.87e-4 (unfavourable), Head and neck cancer:8.83e-4 (unfavourable)",Expressed in all,Tissue enhanced,,kidney: 190.7,liver: 53.7,Cell line enhanced,,Hep G2: 141.9
11,ALDH1L1,"10-fTHF, FTHFD",ENSG00000144908,Aldehyde dehydrogenase 1 family member L1,3,126103562-126197994,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA036900, HPA050139",Enhanced,Supported,Supported,Cytosol,Renal cancer:2.42e-8 (favourable),Tissue enhanced,Tissue enhanced,,kidney: 121.2;liver: 190.4,adipose tissue: 80.9,Cell line enhanced,,Hep G2: 54.9;Karpas-707: 57.9;RT4: 174.8
12,ALDH4A1,"ALDH4, P5CDh",ENSG00000159423,Aldehyde dehydrogenase 4 family member A1,1,18871430-18902781,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB004645, HPA006401",Enhanced,,,,Cervical cancer:5.06e-4 (favourable),Expressed in all,Tissue enhanced,,kidney: 185.7;liver: 108.1,adipose tissue: 63.8,Expressed in all,,
13,ALX1,CART1,ENSG00000180318,ALX homeobox 1,12,85280107-85301784,"Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA001598, HPA018905",Uncertain,,Supported,Nucleoplasm<br>Nuclear bodies<br>Golgi apparatus,,Tissue enriched,Tissue enhanced,,epididymis: 4.3;kidney: 3.1,ovary: 1.8,Cell line enhanced,,HEK93: 19.4;HUVEC TERT2: 13.0;SK-MEL-30: 20.2;THP-1: 11.5;WM-115: 13.3
14,ARSE,"CDPX, CDPX1",ENSG00000157399,Arylsulfatase E (chondrodysplasia punctata 1),X,2934632-2968310,"Disease related genes, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA060518, HPA070651",Approved,,Supported,Golgi apparatus,Colorectal cancer:8.95e-4 (favourable),Mixed,Tissue enhanced,,kidney: 41.3;liver: 49.3,pancreas: 23.9,Cell line enhanced,,A549: 65.1;CACO-2: 37.1;Hep G2: 46.2;NTERA-2: 32.8
15,ASPA,"ACY2, ASP",ENSG00000108381,Aspartoacylase,17,3472374-3503419,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA022142, HPA022145",Enhanced,,Uncertain,Cytosol,,Tissue enhanced,Tissue enhanced,,kidney: 39.8,cerebral cortex: 24.7,Cell line enhanced,,ASC diff: 3.7;HSkMC: 5.5
16,ASPDH,,ENSG00000204653,Aspartate dehydrogenase domain containing,19,50511600-50514690,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA042631, HPA042654",Approved,,,,,Tissue enriched,Tissue enhanced,,cerebral cortex: 17.9;kidney: 27.9;liver: 34.6,duodenum: 6.9,Cell line enhanced,,HEK93: 12.4;MOLT-4: 13.3;SH-SY5Y: 9.8
17,ASS1,"ASS, CTLN1",ENSG00000130707,Argininosuccinate synthase 1,9,130444929-130501274,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA020896, HPA020934",Enhanced,,Approved,Nucleoplasm<br>Cytosol,Endometrial cancer:8.14e-9 (unfavourable),Expressed in all,Tissue enhanced,,kidney: 1259.9;liver: 1027.3,fallopian tube: 261.5,Cell line enhanced,,BJ hTERT+: 709.0;HaCaT: 734.6;RPMI-8226: 956.8;THP-1: 690.3
18,BICC1,,ENSG00000122870,BicC family RNA binding protein 1,10,58513140-58831437,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA045212,Enhanced,,Approved,Nucleoplasm,,Expressed in all,Tissue enhanced,,kidney: 32.0,gallbladder: 19.2,Cell line enhanced,,CACO-2: 79.9;RPTEC TERT1: 112.1
19,BICDL1,"BICDR-1, CCDC64, FLJ26450",ENSG00000135127,BICD family like cargo adaptor 1,12,119989869-120094494,Predicted intracellular proteins,Evidence at protein level,HPA061116,Enhanced,,Approved,Nucleoplasm<br>Vesicles<br>Cytosol,"Stomach cancer:1.21e-5 (favourable), Renal cancer:3.93e-5 (favourable), Head and neck cancer:3.15e-4 (favourable), Cervical cancer:6.50e-4 (favourable), Liver cancer:6.84e-4 (unfavourable)",Expressed in all,Tissue enhanced,,kidney: 73.9;skin: 58.6,epididymis: 45.6,Cell line enhanced,,hTCEpi: 35.3;SCLC-21H: 36.3
20,C14orf105,FLJ10650,ENSG00000100557,Chromosome 14 open reading frame 105,14,57469301-57493867,Predicted intracellular proteins,Evidence at transcript level,HPA029202,,,Uncertain,Nucleus<br>Cytosol,"Renal cancer:1.92e-4 (favourable), Liver cancer:5.61e-4 (unfavourable)",Tissue enhanced,Tissue enhanced,,fallopian tube: 43.7;gallbladder: 27.1;kidney: 63.6,liver: 11.3,Group enriched,6.0,A549: 10.7;RPTEC TERT1: 26.1
21,C21orf62,"B37, C21orf120, PRED81",ENSG00000205929,Chromosome 21 open reading frame 62,21,32793564-32813743,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA016899,Enhanced,,,,Renal cancer:1.14e-4 (favourable),Tissue enriched,Tissue enhanced,,epididymis: 6.4;kidney: 5.1;ovary: 12.6,prostate: 4.2,Group enriched,13.0,AF22: 2.5;RPTEC TERT1: 1.1
22,C9orf66,FLJ31158,ENSG00000183784,Chromosome 9 open reading frame 66,9,212824-215741,Predicted intracellular proteins,Evidence at transcript level,HPA035652,Uncertain,,,,Renal cancer:1.32e-5 (favourable),Tissue enhanced,Tissue enhanced,,kidney: 17.8,adrenal gland: 4.0,Cell line enhanced,,BEWO: 1.5;THP-1: 2.3
23,CA12,HsT18816,ENSG00000074410,Carbonic anhydrase 12,15,63321378-63382161,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,"HPA008773, CAB025181, CAB062549, CAB068179, HPA073203",Enhanced,,Approved,Nucleus<br>Vesicles,Pancreatic cancer:3.80e-6 (unfavourable),Expressed in all,Tissue enhanced,,kidney: 308.4;skin: 168.3,rectum: 102.9,Cell line enhanced,,A549: 191.8;RT4: 180.0;T-47d: 269.1;U-138 MG: 295.7;U-87 MG: 352.6
24,CALCR,CTR,ENSG00000004948,Calcitonin receptor,7,93424487-93574730,"Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA028962, HPA061428",Enhanced,,,,,Tissue enriched,Tissue enhanced,,kidney: 2.1;testis: 1.4,placenta: 1.0,Cell line enhanced,,RPTEC TERT1: 1.5;T-47d: 3.6
25,CDH6,,ENSG00000113361,Cadherin 6,5,31193750-31329146,"Plasma proteins, Predicted membrane proteins",Evidence at protein level,"HPA007047, HPA007456, CAB025274",Enhanced,,,,,Group enriched,Tissue enhanced,,kidney: 16.0,gallbladder: 14.7,Cell line enriched,7.0,EFO-21: 458.4
26,CDH9,,ENSG00000113100,Cadherin 9,5,26880600-27121150,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA007167,Approved,,,,,Not detected,Tissue enhanced,,cerebral cortex: 11.4;kidney: 6.5,testis: 4.3,Cell line enhanced,,K-562: 6.6;NTERA-2: 10.2
27,CH507-9B2.2,,ENSG00000279493,,21,5011799-5017145,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Not detected,Tissue enhanced,,kidney: 1.8;liver: 2.7,lymph node: 0.5,Cell line enhanced,,BEWO: 1.3;CACO-2: 2.4;MCF7: 1.6;SiHa: 3.5
28,CHDH,,ENSG00000016391,Choline dehydrogenase,3,53812335-53846390,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA036633, HPA058130",Enhanced,,,,Renal cancer:1.88e-8 (favourable),Mixed,Tissue enhanced,,kidney: 40.1,small intestine: 16.4,Cell line enhanced,,CACO-2: 9.5;Hep G2: 24.3;T-47d: 10.6
29,CLCN5,"ClC-5, CLC5, DENTS, hCIC-K2, hClC-K2, NPHL1, NPHL2, XLRH, XRN",ENSG00000171365,Chloride voltage-gated channel 5,X,49922615-50099235,"Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA000401, HPA003213",Uncertain,,Supported,Golgi apparatus<br>Plasma membrane<br>Cytosol,"Renal cancer:2.05e-8 (favourable), Pancreatic cancer:5.20e-4 (favourable)",Expressed in all,Tissue enhanced,,epididymis: 33.7;kidney: 52.0,placenta: 9.6,Cell line enhanced,,CACO-2: 44.1;RH-30: 76.7
30,CLCNKB,hClC-Kb,ENSG00000184908,Chloride voltage-gated channel Kb,1,16043736-16057308,"Disease related genes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA057717,Approved,,,,Renal cancer:1.27e-7 (favourable),Tissue enriched,Tissue enhanced,,kidney: 107.9,salivary gland: 22.0,Cell line enhanced,,EFO-21: 1.5
31,CLDN10,"CPETRL3, OSP-L",ENSG00000134873,Claudin 10,13,95433604-95579759,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB012969, HPA042348",Enhanced,,,,"Renal cancer:7.46e-5 (favourable), Thyroid cancer:2.13e-4 (favourable)",Mixed,Tissue enhanced,,kidney: 163.5,"cervix, uterine: 112.6",Cell line enhanced,,EFO-21: 10.0;HUVEC TERT2: 11.9;NTERA-2: 28.0;RPTEC TERT1: 43.5
32,CLDN2,,ENSG00000165376,Claudin 2,X,106900164-106930861,Predicted membrane proteins,Evidence at protein level,"CAB002609, HPA051548",Enhanced,,Supported,Nucleoplasm<br>Cell Junctions,Thyroid cancer:1.70e-4 (favourable),Group enriched,Tissue enhanced,,gallbladder: 159.0;kidney: 171.8;seminal vesicle: 129.3,epididymis: 41.1,Group enriched,23.0,A549: 24.6;CACO-2: 18.2;RPTEC TERT1: 35.1
33,CLDN8,,ENSG00000156284,Claudin 8,21,30214006-30216073,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA060605,Supported,,,,Renal cancer:3.32e-4 (favourable),Tissue enhanced,Tissue enhanced,,breast: 84.9;kidney: 76.1;rectum: 56.0,thyroid gland: 37.3,Cell line enriched,17.0,HaCaT: 30.1
34,CLNK,MIST,ENSG00000109684,Cytokine dependent hematopoietic cell linker,4,10486395-10684865,Predicted intracellular proteins,Evidence at protein level,"HPA035671, HPA035672",Uncertain,,Uncertain,Vesicles,,Tissue enriched,Tissue enhanced,,kidney: 5.8,lymph node: 3.4,Group enriched,6.0,HDLM-2: 3.9;U-937: 1.6
35,CMBL,FLJ23617,ENSG00000164237,Carboxymethylenebutenolidase homolog,5,10275875-10308026,Predicted intracellular proteins,Evidence at protein level,HPA036571,Uncertain,,,,Ovarian cancer:1.99e-4 (favourable),Expressed in all,Tissue enhanced,,kidney: 315.7,duodenum: 177.0,Mixed,,
36,CYP27B1,"CYP1, P450c1, PDDR, VDD1",ENSG00000111012,Cytochrome P450 family 27 subfamily B member 1,12,57762334-57768986,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,,,,,,Thyroid cancer:6.79e-4 (unfavourable),Mixed,Tissue enhanced,,kidney: 4.3;thyroid gland: 3.9,appendix: 1.2,Cell line enriched,8.0,RH-30: 47.8
37,DCDC2,"DCDC2A, DFNB66, KIAA1154, NPHP19, RU2",ENSG00000146038,Doublecortin domain containing 2,6,24171756-24358052,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA031582, HPA031583, HPA031584",Enhanced,,Enhanced,Microtubules<br>Mitotic spindle<br>Microtubule organizing center<br>Cytosol,,Mixed,Tissue enhanced,,kidney: 23.2,parathyroid gland: 15.3,Group enriched,8.0,CACO-2: 59.2;EFO-21: 45.6;Hep G2: 55.9;RPTEC TERT1: 193.3
38,DDC,AADC,ENSG00000132437,Dopa decarboxylase,7,50458436-50565457,"Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins",Evidence at protein level,HPA017742,Enhanced,,Approved,Actin filaments,,Mixed,Tissue enhanced,,duodenum: 155.2;kidney: 320.9;small intestine: 180.5,adrenal gland: 63.8,Group enriched,9.0,CACO-2: 44.3;Hep G2: 32.3;SCLC-21H: 154.0;SH-SY5Y: 144.1
39,DEFB1,"BD1, DEFB-1, DEFB101, HBD-1, HBD1, MGC51822",ENSG00000164825,Defensin beta 1,8,6870575-6878022,"Predicted secreted proteins, Transporters",Evidence at protein level,,,,,,"Renal cancer:1.90e-5 (favourable), Lung cancer:5.62e-4 (unfavourable), Pancreatic cancer:5.94e-4 (unfavourable)",Tissue enhanced,Tissue enhanced,,"cervix, uterine: 618.9;kidney: 1500.2",salivary gland: 232.3,Cell line enhanced,,NB-4: 34.9;SCLC-21H: 45.7;THP-1: 129.4
40,DPEP1,,ENSG00000015413,Dipeptidase 1 (renal),16,89613308-89638456,"Enzymes, FDA approved drug targets, Predicted secreted proteins",Evidence at protein level,"HPA009426, HPA012783",Enhanced,,Approved,Nucleus<br>Cell Junctions,Renal cancer:6.84e-4 (favourable),Tissue enriched,Tissue enhanced,,kidney: 262.6;small intestine: 418.9,pancreas: 92.8,Cell line enhanced,,Hep G2: 22.4;HHSteC: 11.8;U-937: 36.5
41,EMX1,,ENSG00000135638,Empty spiracles homeobox 1,2,72916260-72936071,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA006230, HPA006421",Approved,,Approved,Nucleoli,Renal cancer:1.54e-6 (favourable),Tissue enhanced,Tissue enhanced,,cerebral cortex: 8.3;kidney: 15.5;parathyroid gland: 5.0,testis: 2.6,Cell line enhanced,,BEWO: 2.2;CACO-2: 3.1;HEK93: 7.5
42,ENAM,AIH2,ENSG00000132464,Enamelin,4,70628744-70686816,"Disease related genes, Predicted secreted proteins",Evidence at protein level,,,,,,Renal cancer:1.81e-14 (favourable),Tissue enhanced,Tissue enhanced,,epididymis: 8.3;kidney: 5.9,heart muscle: 2.4,Not detected,,
43,ENPP6,MGC33971,ENSG00000164303,Ectonucleotide pyrophosphatase/phosphodiesterase 6,4,184088706-184221230,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA042740,Approved,,Approved,Golgi apparatus,,Tissue enriched,Tissue enhanced,,kidney: 30.6;ovary: 15.0,cerebral cortex: 8.6,Cell line enhanced,,Karpas-707: 2.3;SH-SY5Y: 3.8;U-266/70: 2.2;U-266/84: 1.1
44,ESM1,,ENSG00000164283,Endothelial cell specific molecule 1,5,54977864-55022671,Predicted secreted proteins,Evidence at protein level,,,,,,"Cervical cancer:2.11e-7 (unfavourable), Renal cancer:4.00e-4 (unfavourable)",Tissue enriched,Tissue enhanced,,kidney: 19.2;thyroid gland: 27.2,endometrium: 5.8,Group enriched,5.0,HUVEC TERT2: 236.2;TIME: 434.9
45,ETNK2,"EKI2, FLJ10761",ENSG00000143845,Ethanolamine kinase 2,1,204131062-204152003,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA057167,Enhanced,,,,"Glioma:3.43e-4 (unfavourable), Renal cancer:6.50e-4 (favourable)",Expressed in all,Tissue enhanced,,kidney: 110.6;liver: 120.7;testis: 143.1,ovary: 43.4,Mixed,,
46,FAM131C,"C1orf117, FLJ36766",ENSG00000185519,Family with sequence similarity 131 member C,1,16057769-16073632,Predicted intracellular proteins,Evidence at protein level,HPA031046,Uncertain,,Approved,Nucleoli<br>Intermediate filaments<br>Cytosol,Renal cancer:9.33e-6 (favourable),Mixed,Tissue enhanced,,adrenal gland: 3.3;cerebral cortex: 4.8;kidney: 3.7,"heart muscle,skin: 1.1",Cell line enhanced,,A549: 7.2;HEK93: 4.6;PC-3: 5.4
47,FAM24B,"AC073585.2, MGC45962",ENSG00000213185,Family with sequence similarity 24 member B,10,122849078-122879641,Predicted intracellular proteins,Evidence at protein level,HPA052490,Supported,,,,,Expressed in all,Tissue enhanced,,kidney: 13.8,testis: 11.4,Group enriched,5.0,hTERT-HME1: 99.8;LHCN-M2: 139.2;TIME: 44.7
48,FCAMR,"CD351, FCA/MR, FKSG87",ENSG00000162897,Fc fragment of IgA and IgM receptor,1,206957965-206970625,"CD markers, Predicted membrane proteins",Evidence at protein level,HPA056505,Enhanced,,,,,Tissue enhanced,Tissue enhanced,,kidney: 32.1;lymph node: 14.0;tonsil: 11.3,appendix: 5.2,Not detected,,
49,FGF1,"AFGF, ECGF, ECGF-beta, ECGFA, ECGFB, FGF-alpha, FGFA, GLIO703, HBGF1",ENSG00000113578,Fibroblast growth factor 1,5,142592178-142698070,"Cancer-related genes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,"HPA003265, CAB017519",Enhanced,,,,"Renal cancer:2.59e-5 (favourable), Thyroid cancer:3.45e-5 (favourable)",Tissue enriched,Tissue enhanced,,cerebral cortex: 129.9;kidney: 59.4,heart muscle: 32.8,Cell line enhanced,,BJ: 37.6;BJ hTERT+ SV40 Large T+: 33.4;BJ hTERT+ SV40 Large T+ RasG12V: 43.9;HBF TERT88: 62.3;hTEC/SVTERT24-B: 45.5;U-2 OS: 33.6
50,FGF9,,ENSG00000102678,Fibroblast growth factor 9,13,21671383-21704498,"Cancer-related genes, Disease related genes, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,HPA067007,Enhanced,,,,Renal cancer:1.70e-6 (favourable),Tissue enhanced,Tissue enhanced,,kidney: 12.1,adrenal gland: 4.7,Cell line enhanced,,RPTEC TERT1: 2.5;SCLC-21H: 8.0
51,FIGNL2,,ENSG00000261308,Fidgetin like 2,12,51817840-51848766,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Mixed,Tissue enhanced,,kidney: 2.3;parathyroid gland: 2.4,placenta: 1.1,Cell line enhanced,,AF22: 17.1;BEWO: 10.8;NTERA-2: 6.9
52,FMO4,FMO2,ENSG00000076258,Flavin containing monooxygenase 4,1,171314208-171342084,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA049100,Uncertain,,,,"Liver cancer:1.09e-4 (favourable), Renal cancer:6.96e-4 (favourable), Lung cancer:7.45e-4 (favourable)",Expressed in all,Tissue enhanced,,kidney: 48.2;liver: 30.1,parathyroid gland: 10.9,Cell line enhanced,,EFO-21: 5.2
53,FOXI1,"FKHL10, FREAC6",ENSG00000168269,Forkhead box I1,5,170105897-170109725,"Plasma proteins, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA071469,Enhanced,,Uncertain,Nucleoli<br>Vesicles,,Group enriched,Tissue enhanced,,breast: 10.4;kidney: 20.0,salivary gland: 6.2,Cell line enhanced,,MCF7: 1.2
54,FREM2,DKFZp686J0811,ENSG00000150893,FRAS1 related extracellular matrix protein 2,13,38687129-38887131,"Disease related genes, Predicted membrane proteins",Evidence at protein level,HPA028831,Uncertain,,Approved,Cytosol,Renal cancer:2.23e-7 (favourable),Mixed,Tissue enhanced,,kidney: 8.2;thyroid gland: 8.3,lung: 3.3,Cell line enhanced,,AF22: 15.4;HAP1: 10.9;MCF7: 6.0;RT4: 5.7;WM-115: 5.8
55,FRMD7,"FLJ43346, NYS, NYS1",ENSG00000165694,FERM domain containing 7,X,132076993-132128020,"Cancer-related genes, Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA000886,Uncertain,,,,,Not detected,Tissue enhanced,,endometrium: 2.8;kidney: 3.0;smooth muscle: 3.5,seminal vesicle: 0.7,Cell line enhanced,,U-87 MG: 1.5
56,FUT6,"FCT3A, FLJ40754, FT1A, FucT-VI",ENSG00000156413,Fucosyltransferase 6,19,5830610-5839731,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA043707, HPA046966",Approved,,Supported,Golgi apparatus,"Renal cancer:3.17e-8 (favourable), Head and neck cancer:2.12e-4 (favourable)",Mixed,Tissue enhanced,,esophagus: 49.8;kidney: 34.5,small intestine: 30.6,Group enriched,5.0,Hep G2: 7.2;RPMI-8226: 2.7
57,FXYD6-FXYD2,,ENSG00000255245,FXYD6-FXYD2 readthrough,11,117820163-117876667,Predicted membrane proteins,Evidence at transcript level,"HPA068838, HPA075209",Approved,,Approved,Nuclear membrane<br>Vesicles,,Not detected,Tissue enhanced,,kidney: 5.6,salivary gland: 2.1,Group enriched,6.0,MOLT-4: 5.2;RPTEC TERT1: 5.3
58,G6PC,"G6PT, GSD1a",ENSG00000131482,Glucose-6-phosphatase catalytic subunit,17,42900797-42913369,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,HPA052324,Enhanced,,,,"Renal cancer:3.79e-5 (favourable), Liver cancer:5.42e-5 (favourable)",Tissue enriched,Tissue enhanced,,kidney: 89.1;liver: 147.3,small intestine: 33.2,Not detected,,
59,GALNT14,"FLJ12691, GalNac-T10, GalNac-T14",ENSG00000158089,Polypeptide N-acetylgalactosaminyltransferase 14,2,30910467-31155202,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA030138,,,Approved,Nucleus<br>Golgi apparatus,,Tissue enriched,Tissue enhanced,,kidney: 40.3,parathyroid gland: 12.8,Cell line enhanced,,RPTEC TERT1: 29.5;RT4: 23.6;SCLC-21H: 25.2
60,GDF3,,ENSG00000184344,Growth differentiation factor 3,12,7689782-7695776,"Disease related genes, Predicted secreted proteins",Evidence at protein level,HPA018468,Uncertain,,,,,Tissue enriched,Tissue enhanced,,kidney: 1.1;spleen: 1.1,testis: 0.8,Cell line enriched,14.0,NTERA-2: 450.4
61,GGH,,ENSG00000137563,Gamma-glutamyl hydrolase,8,63015079-63039171,"Enzymes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"CAB019296, HPA025226",Approved,,,,"Endometrial cancer:3.99e-7 (unfavourable), Lung cancer:1.65e-4 (unfavourable)",Expressed in all,Tissue enhanced,,kidney: 90.0,liver: 63.2,Mixed,,
62,GGT1,"CD224, D22S672, D22S732, GGT",ENSG00000100031,Gamma-glutamyltransferase 1,22,24583750-24629005,"Candidate cardiovascular disease genes, CD markers, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA045635, HPA047534, HPA065444",Supported,,Approved,Vesicles,"Renal cancer:4.83e-4 (favourable), Ovarian cancer:7.44e-4 (favourable)",Expressed in all,Tissue enhanced,,kidney: 161.2,small intestine: 95.9,Cell line enhanced,,HDLM-2: 148.2;Karpas-707: 162.6;RPMI-8226: 159.9;RPTEC TERT1: 155.8
63,GK,"GK1, GKD",ENSG00000198814,Glycerol kinase,X,30653359-30731456,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA060687,Supported,,,,Renal cancer:3.24e-9 (favourable),Expressed in all,Tissue enhanced,,kidney: 111.0,small intestine: 98.6,Mixed,,
64,GLDC,"GCSP, NKH",ENSG00000178445,Glycine decarboxylase,9,6532464-6645783,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA002318, HPA052887",Enhanced,,Supported,Nucleus<br>Mitochondria,"Endometrial cancer:5.24e-5 (unfavourable), Renal cancer:3.50e-4 (favourable)",Tissue enhanced,Tissue enhanced,,kidney: 30.3;liver: 19.9;placenta: 20.1,cerebral cortex: 10.6,Cell line enhanced,,BEWO: 206.9;RPTEC TERT1: 67.4
65,GLOD5,,ENSG00000171433,Glyoxalase domain containing 5,X,48761750-48773648,Predicted intracellular proteins,Evidence at protein level,HPA010667,Uncertain,,Uncertain,Mitochondria,,Mixed,Tissue enhanced,,duodenum: 10.8;kidney: 11.0;small intestine: 10.7,epididymis: 6.8,Cell line enhanced,,MCF7: 1.6
66,GLTPD2,,ENSG00000182327,Glycolipid transfer protein domain containing 2,17,4788959-4790390,Predicted secreted proteins,Evidence at protein level,"HPA058295, HPA065267",Uncertain,,Approved,Vesicles,,Tissue enriched,Tissue enhanced,,duodenum: 11.0;kidney: 12.8;liver: 13.8,small intestine: 7.2,Cell line enhanced,,CACO-2: 8.6;Hep G2: 9.4
67,GPAT3,"AGPAT10, AGPAT9, HMFN0839, LPAAT-theta, MAG1, MGC11324",ENSG00000138678,Glycerol-3-phosphate acyltransferase 3,4,83535914-83605875,"Enzymes, Predicted membrane proteins",Evidence at protein level,"HPA029414, CAB033749",Approved,,Uncertain,Plasma membrane<br>Cytosol,"Renal cancer:2.71e-9 (favourable), Urothelial cancer:8.21e-4 (unfavourable)",Mixed,Tissue enhanced,,kidney: 89.9,duodenum: 40.7,Cell line enhanced,,CAPAN-2: 141.3;U-87 MG: 67.1;WM-115: 52.9
68,GPC5,,ENSG00000179399,Glypican 5,13,91398607-92873682,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA040152, HPA044081",Enhanced,,Approved,Nucleus<br>Cytosol,Glioma:5.67e-4 (unfavourable),Tissue enhanced,Tissue enhanced,,cerebral cortex: 15.8;kidney: 8.1;testis: 11.5,lung: 4.9,Group enriched,9.0,CACO-2: 41.2;HeLa: 18.9
69,GRB14,,ENSG00000115290,Growth factor receptor bound protein 14,2,164492812-164621848,Predicted intracellular proteins,Evidence at protein level,"CAB022294, HPA035052, HPA035053",Uncertain,,Approved,Nucleoplasm<br>Cytosol,,Mixed,Tissue enhanced,,epididymis: 6.1;kidney: 6.2;liver: 6.6,testis: 4.3,Cell line enhanced,,HUVEC TERT2: 7.9;RPTEC TERT1: 5.9;TIME: 9.9
70,GSTA1,,ENSG00000243955,Glutathione S-transferase alpha 1,6,52791664-52803910,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA004342, HPA048934, HPA053817",Supported,,Supported,Cytosol,"Renal cancer:3.71e-4 (unfavourable), Lung cancer:8.66e-4 (favourable)",Group enriched,Tissue enhanced,,adrenal gland: 1136.4;kidney: 1310.9;liver: 1757.6,small intestine: 1002.9,Cell line enriched,11.0,Hep G2: 245.8
71,HECW1,"KIAA0322, NEDL1",ENSG00000002746,"HECT, C2 and WW domain containing E3 ubiquitin protein ligase 1",7,43112599-43566001,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA007203, HPA007593, HPA007609",Approved,,Supported,Cytosol,,Not detected,Tissue enhanced,,cerebral cortex: 10.9;kidney: 8.2,testis: 3.4,Cell line enhanced,,A549: 3.9;U-266/70: 9.1
72,HGD,"AKU, HGO",ENSG00000113924,"Homogentisate 1,2-dioxygenase",3,120628173-120682571,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA047374, HPA052359",Enhanced,,Supported,Golgi apparatus,Endometrial cancer:1.78e-4 (favourable),Tissue enhanced,Tissue enhanced,,kidney: 175.8;liver: 324.3,gallbladder: 87.1,Group enriched,10.0,CACO-2: 38.8;EFO-21: 75.8;Hep G2: 110.3;RPTEC TERT1: 153.1
73,HNF1A,"HNF1, LFB1, MODY3, TCF1",ENSG00000135100,HNF1 homeobox A,12,120978543-121002512,"Cancer-related genes, Predicted intracellular proteins",Evidence at protein level,"CAB010430, HPA035231",Enhanced,,Supported,Nucleoplasm,,Mixed,Tissue enhanced,,duodenum: 15.5;kidney: 10.6;small intestine: 15.7,liver: 6.3,Group enriched,7.0,A549: 8.0;CACO-2: 24.3;Hep G2: 22.1
74,HNF1B,"HNF1beta, LFB3, MODY5, TCF2, VHNF1",ENSG00000275410,HNF1 homeobox B,17,37686432-37745247,"Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA002083, CAB068192",Enhanced,,Supported,Nucleoplasm,"Urothelial cancer:2.51e-6 (favourable), Renal cancer:6.00e-4 (favourable)",Tissue enhanced,Tissue enhanced,,gallbladder: 21.5;kidney: 25.3,lung: 9.6,Cell line enhanced,,A549: 16.8;CACO-2: 17.9;EFO-21: 26.2;RPTEC TERT1: 95.5
75,HOGA1,"C10orf65, DHDPS2, DHDPSL, FLJ37472, NPL2",ENSG00000241935,4-hydroxy-2-oxoglutarate aldolase 1,10,97584323-97612802,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA039466,Approved,,,,Renal cancer:9.08e-4 (favourable),Group enriched,Tissue enhanced,,kidney: 53.4;liver: 20.7,heart muscle: 8.5,Cell line enhanced,,EFO-21: 9.0;Hep G2: 17.6;RPTEC TERT1: 23.2
76,HOXD8,"HOX4, HOX4E",ENSG00000175879,Homeobox D8,2,176129694-176132695,"Predicted intracellular proteins, Transcription factors",Evidence at transcript level,,,,,,Lung cancer:3.78e-4 (unfavourable),Mixed,Tissue enhanced,,epididymis: 122.0;kidney: 83.6,ovary: 43.1,Cell line enhanced,,RPTEC TERT1: 56.9
77,HPN,TMPRSS1,ENSG00000105707,Hepsin,19,35040506-35066571,"Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA006804,Approved,,,,Renal cancer:5.45e-5 (favourable),Tissue enhanced,Tissue enhanced,,kidney: 99.7;liver: 155.4,prostate: 31.6,Group enriched,7.0,EFO-21: 29.1;Hep G2: 31.2;T-47d: 20.3
78,HS6ST2,,ENSG00000171004,Heparan sulfate 6-O-sulfotransferase 2,X,132626016-132961395,"Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA034625, HPA034626",Uncertain,,Supported,Nucleoplasm,Urothelial cancer:6.03e-4 (favourable),Mixed,Tissue enhanced,,kidney: 15.0;ovary: 17.6,placenta: 11.9,Cell line enhanced,,HEK93: 42.3;RH-30: 63.9;SH-SY5Y: 87.0
79,HSD11B2,SDR9C3,ENSG00000176387,Hydroxysteroid 11-beta dehydrogenase 2,16,67430652-67437553,"Disease related genes, Predicted membrane proteins",Evidence at protein level,"CAB032443, HPA042186, HPA056385",Enhanced,,Approved,Vesicles,Renal cancer:9.51e-5 (favourable),Expressed in all,Tissue enhanced,,colon: 151.6;kidney: 173.3,salivary gland: 122.5,Cell line enhanced,,NTERA-2: 11.4;RPMI-8226: 9.6;RT4: 11.0;SCLC-21H: 17.5;SK-BR-3: 10.0
80,IL17RB,"CRL4, EVI27, IL17BR, IL17RH1",ENSG00000056736,Interleukin 17 receptor B,3,53846580-53865800,Predicted membrane proteins,Evidence at protein level,HPA005482,Supported,,,,Renal cancer:6.61e-4 (favourable),Expressed in all,Tissue enhanced,,kidney: 61.7,"cervix, uterine: 29.4",Cell line enhanced,,Hep G2: 40.4
81,INSRR,IRR,ENSG00000027644,Insulin receptor related receptor,1,156840063-156859018,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA025285,Uncertain,,,,,Not detected,Tissue enhanced,,adrenal gland: 1.8;kidney: 1.4;testis: 2.2,prostate: 0.6,Group enriched,10.0,SCLC-21H: 5.5;SH-SY5Y: 17.2
82,IRX1,IRX-5,ENSG00000170549,Iroquois homeobox 1,5,3596054-3601403,"Plasma proteins, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA043160,Uncertain,,Approved,Nucleoplasm<br>Golgi apparatus,,Group enriched,Tissue enhanced,,breast: 7.7;kidney: 5.3;salivary gland: 5.7,lung: 3.6,Cell line enhanced,,AF22: 9.8;REH: 38.0;U-251 MG: 13.8
83,KCNH6,"erg2, HERG2, Kv11.2",ENSG00000173826,Potassium voltage-gated channel subfamily H member 6,17,63523334-63548977,"Predicted membrane proteins, Voltage-gated ion channels",Evidence at protein level,,,,,,,Tissue enhanced,Tissue enhanced,,kidney: 6.1;prostate: 5.4;small intestine: 5.5,duodenum: 2.2,Group enriched,6.0,SCLC-21H: 4.0;SH-SY5Y: 1.4
84,KCNJ15,"IRKK, Kir1.3, Kir4.2",ENSG00000157551,Potassium voltage-gated channel subfamily J member 15,21,38157034-38307357,"Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels",Evidence at protein level,HPA016702,Approved,,Approved,Vesicles<br>Plasma membrane<br>Cytosol,"Renal cancer:4.09e-10 (favourable), Urothelial cancer:1.95e-4 (favourable)",Tissue enhanced,Tissue enhanced,,kidney: 261.3;thyroid gland: 216.3,lung: 63.4,Cell line enhanced,,ASC TERT1: 48.4;HBEC3-KT: 50.0;RPTEC TERT1: 51.4;RT4: 65.6
85,KCP,"CRIM2, FLJ33365, NET67",ENSG00000135253,Kielin/chordin-like protein,7,128862451-128910719,Predicted secreted proteins,Evidence at transcript level,,,,,,,Mixed,Tissue enhanced,,kidney: 2.7;seminal vesicle: 3.3,gallbladder: 1.5,Cell line enhanced,,CAPAN-2: 8.4;HMC-1: 4.7;U-87 MG: 2.3
86,KIF12,,ENSG00000136883,Kinesin family member 12,9,114086126-114099291,Predicted intracellular proteins,Evidence at protein level,"HPA020192, HPA024127",Uncertain,,Approved,Nucleoplasm,,Mixed,Tissue enhanced,,gallbladder: 36.6;kidney: 46.9,thyroid gland: 33.0,Cell line enhanced,,CACO-2: 6.3;RPTEC TERT1: 31.9;SCLC-21H: 7.6
87,KLHDC7A,FLJ38753,ENSG00000179023,Kelch domain containing 7A,1,18480982-18486126,Predicted intracellular proteins,Evidence at protein level,HPA056616,Uncertain,,Approved,Nuclear speckles,"Renal cancer:7.81e-9 (favourable), Urothelial cancer:1.88e-4 (favourable)",Tissue enhanced,Tissue enhanced,,kidney: 20.8,urinary bladder: 6.4,Cell line enhanced,,A549: 4.7;CAPAN-2: 8.9;EFO-21: 4.8;NTERA-2: 5.6;RPTEC TERT1: 8.6;RT4: 7.4;T-47d: 9.5
88,KMO,,ENSG00000117009,Kynurenine 3-monooxygenase,1,241532134-241595642,"Enzymes, Predicted membrane proteins",Evidence at protein level,"HPA031115, HPA056942",Enhanced,,,,Renal cancer:6.49e-8 (unfavourable),Mixed,Tissue enhanced,,kidney: 32.3;liver: 47.7,spleen: 10.8,Cell line enhanced,,RPMI-8226: 6.1;RPTEC TERT1: 16.3;SK-BR-3: 8.4;U-698: 6.4
89,LGSN,"GLULD1, LGS",ENSG00000146166,"Lengsin, lens protein with glutamine synthetase domain",6,63275951-63319977,Predicted intracellular proteins,Evidence at protein level,"HPA030957, HPA039983",Enhanced,,Approved,Nucleoplasm<br>Vesicles,,Tissue enhanced,Tissue enhanced,,kidney: 2.8;liver: 2.4;placenta: 1.8,testis: 0.7,Cell line enhanced,,A549: 5.5;BEWO: 3.0;CACO-2: 1.6;HeLa: 1.5
90,MEI4,,ENSG00000269964,Meiotic double-stranded break formation protein 4,6,77690658-77926974,Predicted secreted proteins,Evidence at transcript level,,,,,,,Tissue enhanced,Tissue enhanced,,kidney: 4.5;testis: 4.8;thyroid gland: 3.9,adrenal gland: 0.9,Not detected,,
91,MFSD4A,"DKFZp761N1114, FLJ25004, FLJ34577, MFSD4, UNQ3064",ENSG00000174514,Major facilitator superfamily domain containing 4A,1,205568885-205602918,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,,,,,,"Renal cancer:2.27e-13 (favourable), Lung cancer:4.59e-4 (favourable), Cervical cancer:7.54e-4 (favourable)",Mixed,Tissue enhanced,,kidney: 75.4;stomach: 111.7,cerebral cortex: 50.6,Cell line enhanced,,HMC-1: 1.3;SCLC-21H: 1.9
92,MME,"CALLA, CD10, NEP",ENSG00000196549,Membrane metalloendopeptidase,3,155024124-155183729,"Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB000013, HPA052583, HPA056072",Enhanced,,,,,Mixed,Tissue enhanced,,duodenum: 428.2;kidney: 384.2;small intestine: 401.5,prostate: 162.5,Cell line enhanced,,ASC TERT1: 595.9;BJ hTERT+: 1084.7;HSkMC: 604.7
93,MRO,"B29, C18orf3, FLJ30140",ENSG00000134042,Maestro,18,50795120-50825402,Predicted intracellular proteins,Evidence at transcript level,HPA022011,Approved,,,,,Tissue enriched,Tissue enhanced,,cerebral cortex: 27.5;kidney: 25.5;testis: 54.7,thyroid gland: 10.4,Cell line enhanced,,ASC diff: 1.9;ASC TERT1: 6.0
94,MT1F,MT1,ENSG00000198417,Metallothionein 1F,16,56657694-56660698,Predicted intracellular proteins,Evidence at protein level,,,,,,Renal cancer:2.02e-7 (unfavourable),Expressed in all,Tissue enhanced,,kidney: 285.2;thyroid gland: 817.7,small intestine: 138.4,Cell line enhanced,,HDLM-2: 71.6;NB-4: 79.2;NTERA-2: 77.1;RPTEC TERT1: 250.9
95,MT1G,"MT1, MT1K",ENSG00000125144,Metallothionein 1G,16,56666731-56668065,"Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,,,,,,Renal cancer:1.67e-7 (unfavourable),Expressed in all,Tissue enhanced,,kidney: 2350.1;thyroid gland: 4892.2,liver: 1276.9,Cell line enriched,5.0,U-937: 867.7
96,MT1H,MT1,ENSG00000205358,Metallothionein 1H,16,56669814-56671129,Predicted intracellular proteins,Evidence at protein level,,,,,,"Glioma:4.29e-7 (unfavourable), Renal cancer:5.44e-5 (unfavourable)",Tissue enhanced,Tissue enhanced,,kidney: 501.3;small intestine: 335.4;thyroid gland: 541.2,liver: 136.0,Cell line enhanced,,BEWO: 1.1;EFO-21: 3.4;SCLC-21H: 1.0
97,MTNR1A,MEL-1A-R,ENSG00000168412,Melatonin receptor 1A,4,186533655-186555567,"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters",Evidence at protein level,,,,,,,Not detected,Tissue enhanced,,kidney: 2.2;testis: 1.9,colon: 1.2,Not detected,,
98,NELL1,"FLJ45906, IDH3GL",ENSG00000165973,Neural EGFL like 1,11,20669551-21575681,Predicted secreted proteins,Evidence at protein level,HPA051535,Approved,,,,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 22.9;kidney: 18.8,prostate: 8.8,Cell line enhanced,,HAP1: 4.3;SH-SY5Y: 2.0;U-2 OS: 1.1;WM-115: 1.2
99,NPHS1,"CNF, NPHN",ENSG00000161270,"NPHS1, nephrin",19,35825964-35869287,"Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,CAB035555,Enhanced,,,,,Mixed,Tissue enhanced,,kidney: 17.7;lymph node: 5.4;pancreas: 5.5,tonsil: 2.3,Cell line enhanced,,HMC-1: 1.1
100,OGDHL,FLJ10851,ENSG00000197444,Oxoglutarate dehydrogenase-like,10,49734643-49762379,"Citric acid cycle related proteins, Predicted intracellular proteins",Evidence at protein level,HPA052497,Enhanced,,Approved,Nucleus<br>Nucleoli fibrillar center<br>Cytosol,Renal cancer:1.21e-14 (favourable),Tissue enhanced,Tissue enhanced,,kidney: 128.4;parathyroid gland: 56.3,liver: 41.6,Cell line enhanced,,AN3-CA: 19.8;RPTEC TERT1: 32.9;SH-SY5Y: 17.3
101,PAH,PH,ENSG00000171759,Phenylalanine hydroxylase,12,102836885-102958410,"Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA028407, HPA031642",Enhanced,,Approved,Endoplasmic reticulum<br>Vesicles,Liver cancer:4.30e-4 (favourable),Tissue enriched,Tissue enhanced,,kidney: 504.6;liver: 722.4,gallbladder: 125.9,Cell line enriched,26.0,Hep G2: 161.3
102,PANK1,"MGC24596, PANK, PANK1a, PANK1b",ENSG00000152782,Pantothenate kinase 1,10,89579497-89645572,"Enzymes, Predicted intracellular proteins",Evidence at protein level,,,,,,"Renal cancer:1.55e-10 (favourable), Liver cancer:1.50e-4 (favourable)",Mixed,Tissue enhanced,,kidney: 46.6;liver: 55.1,duodenum: 20.6,Mixed,,
103,PAQR5,"FLJ20190, MPRG",ENSG00000137819,Progestin and adipoQ receptor family member 5,15,69298947-69407780,Predicted membrane proteins,Evidence at protein level,HPA076729,,,Approved,Vesicles,"Renal cancer:1.47e-14 (favourable), Pancreatic cancer:2.15e-5 (unfavourable)",Mixed,Tissue enhanced,,kidney: 55.8,adrenal gland: 20.8,Cell line enhanced,,A549: 34.9;CAPAN-2: 40.4;HMC-1: 69.7
104,PCK1,PEPCK-C,ENSG00000124253,Phosphoenolpyruvate carboxykinase 1,20,57561080-57568112,"Citric acid cycle related proteins, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA006277, HPA006507, CAB017027",Approved,,,,Renal cancer:1.47e-5 (favourable),Tissue enriched,Tissue enhanced,,kidney: 425.9;liver: 319.7,small intestine: 157.6,Cell line enriched,9.0,ASC diff: 14.0
105,PCSK1N,"BigLEN, PEN, proSAAS, SAAS, SCG8, SgVIII",ENSG00000102109,Proprotein convertase subtilisin/kexin type 1 inhibitor,X,48831094-48835633,Predicted secreted proteins,Evidence at protein level,"HPA003925, HPA064734",Enhanced,,Approved,Vesicles,"Endometrial cancer:1.15e-4 (unfavourable), Renal cancer:1.36e-4 (favourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 93.6;kidney: 65.7,adrenal gland: 28.5,Cell line enhanced,,HEK93: 52.2;PC-3: 133.3;SCLC-21H: 66.4;SH-SY5Y: 55.2;SiHa: 53.6;U-266/84: 49.2
106,PDZD3,"FLJ22756, IKEPP, PDZK2",ENSG00000172367,PDZ domain containing 3,11,119185457-119190223,Predicted intracellular proteins,Evidence at protein level,,,,,,,Tissue enhanced,Tissue enhanced,,duodenum: 17.3;kidney: 10.8;small intestine: 21.2,rectum: 6.7,Not detected,,
107,PDZK1,"NHERF3, PDZD1",ENSG00000174827,PDZ domain containing 1,1,145670852-145708148,Predicted intracellular proteins,Evidence at protein level,"HPA005755, HPA006155, CAB008971",Enhanced,,Approved,Nucleoplasm<br>Vesicles<br>Cytosol,Renal cancer:2.54e-7 (favourable),Group enriched,Tissue enhanced,,kidney: 561.5;small intestine: 127.1,duodenum: 69.0,Cell line enhanced,,CACO-2: 83.6;RPTEC TERT1: 168.6;T-47d: 547.9
108,PKLR,,ENSG00000143627,"Pyruvate kinase, liver and RBC",1,155289839-155301434,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA006653, CAB034376, CAB034378",Enhanced,,Approved,Endoplasmic reticulum<br>Golgi apparatus,,Tissue enriched,Tissue enhanced,,kidney: 14.0;liver: 26.4,bone marrow: 7.8,Cell line enriched,16.0,K-562: 72.0
109,PM20D1,"Cps1, FLJ32569",ENSG00000162877,Peptidase M20 domain containing 1,1,205828022-205850132,"Enzymes, Predicted secreted proteins",Evidence at transcript level,,,,,,,Tissue enriched,Tissue enhanced,,kidney: 6.0;pancreas: 16.6,skin: 3.9,Cell line enriched,10.0,Karpas-707: 1.3
110,PRR35,C16orf11,ENSG00000161992,Proline rich 35,16,560422-565528,Predicted intracellular proteins,Evidence at transcript level,HPA069297,Uncertain,,,,,Not detected,Tissue enhanced,,kidney: 2.9,testis: 0.8,Not detected,,
111,PTGER1,EP1,ENSG00000160951,Prostaglandin E receptor 1,19,14472466-14475362,"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters",Evidence at transcript level,,,,,,,Tissue enhanced,Tissue enhanced,,kidney: 2.9;spleen: 2.5,lung: 0.7,Cell line enhanced,,HEL: 2.2;PC-3: 2.9;SH-SY5Y: 1.9
112,PTH1R,"PTHR, PTHR1",ENSG00000160801,Parathyroid hormone 1 receptor,3,46877746-46903799,"Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,HPA007978,Approved,,,,Renal cancer:6.79e-6 (favourable),Tissue enhanced,Tissue enhanced,,kidney: 158.9,adrenal gland: 36.7,Cell line enriched,8.0,RPTEC TERT1: 88.0
113,RALYL,HNRPCL3,ENSG00000184672,RALY RNA binding protein-like,8,84182787-84921844,Predicted intracellular proteins,Evidence at protein level,"HPA055868, HPA059112",Enhanced,,Approved,Nucleoplasm,,Tissue enhanced,Tissue enhanced,,adrenal gland: 26.1;cerebral cortex: 49.2;kidney: 19.7,gallbladder: 8.1,Cell line enhanced,,AF22: 4.0
114,RANBP3L,FLJ25422,ENSG00000164188,RAN binding protein 3 like,5,36248434-36302114,Predicted intracellular proteins,Evidence at protein level,"HPA037471, HPA037472, HPA061526",Approved,,Uncertain,Nucleoplasm,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 31.0;kidney: 28.7;prostate: 23.0,breast: 10.0,Cell line enhanced,,ASC diff: 8.5;HSkMC: 1.8;T-47d: 2.0
115,RBP5,CRBPIII,ENSG00000139194,Retinol binding protein 5,12,7123684-7128942,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA038723,Enhanced,,Approved,Golgi apparatus<br>Vesicles,"Urothelial cancer:3.68e-4 (favourable), Lung cancer:8.37e-4 (favourable)",Group enriched,Tissue enhanced,,kidney: 455.7;liver: 204.9,spleen: 102.0,Cell line enhanced,,Hep G2: 17.0;K-562: 46.6
116,REN,,ENSG00000143839,Renin,1,204154819-204190324,"Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA005131, CAB025903",Approved,,,,Renal cancer:6.45e-5 (unfavourable),Tissue enriched,Tissue enhanced,,kidney: 51.2;placenta: 21.0,endometrium: 8.9,Cell line enhanced,,BJ: 1.7;HMC-1: 2.3;SK-BR-3: 1.4
117,RHBG,SLC42A2,ENSG00000132677,Rh family B glycoprotein (gene/pseudogene),1,156369212-156385219,"Predicted membrane proteins, Transporters",Evidence at protein level,"HPA042726, HPA048489",Enhanced,,Approved,Nucleoplasm,Urothelial cancer:8.06e-4 (favourable),Group enriched,Tissue enhanced,,kidney: 3.5;ovary: 2.1,"esophagus,liver: 0.6",Group enriched,28.0,CACO-2: 2.1;Hep G2: 2.0;RT4: 4.3
118,RIPPLY1,,ENSG00000147223,Ripply transcriptional repressor 1,X,106900063-106903335,Predicted secreted proteins,Evidence at protein level,HPA052284,Uncertain,,,,,Group enriched,Tissue enhanced,,kidney: 2.3;liver: 3.0,seminal vesicle: 1.2,Cell line enriched,11.0,RH-30: 6.3
119,RP11-606E8.2,,ENSG00000284057,,11,93741664-93812378,Predicted intracellular proteins,Evidence at protein level,"HPA040511, HPA064236",Approved,,Approved,Nucleoplasm<br>Vesicles,,,Tissue enhanced,,kidney: 6.9,duodenum: 3.1,Mixed,,
120,RP4-583P15.14,,ENSG00000273047,,20,63738270-63740398,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Not detected,Tissue enhanced,,kidney: 1.1;liver: 2.4;urinary bladder: 1.3,adipose tissue: 1.0,Cell line enhanced,,Hep G2: 4.0;HHSteC: 1.0;U-698: 1.5
121,SCNN1G,"ENaCgamma, SCNEG",ENSG00000166828,Sodium channel epithelial 1 gamma subunit,16,23182715-23216883,"Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,HPA071194,,,Supported,Nucleoplasm<br>Plasma membrane,Renal cancer:3.20e-7 (unfavourable),Tissue enhanced,Tissue enhanced,,"cervix, uterine: 24.6;kidney: 46.7",thyroid gland: 9.5,Group enriched,5.0,hTCEpi: 33.4;RT4: 17.1
122,SFXN2,,ENSG00000156398,Sideroflexin 2,10,102714538-102743492,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA018150, HPA026834",Enhanced,,Approved,Mitochondria,"Renal cancer:2.28e-5 (favourable), Cervical cancer:2.28e-4 (favourable), Urothelial cancer:6.52e-4 (favourable), Liver cancer:9.95e-4 (favourable)",Expressed in all,Tissue enhanced,,kidney: 18.7,parathyroid gland: 12.4,Cell line enhanced,,T-47d: 35.9
123,SHISA3,hShisa3,ENSG00000178343,Shisa family member 3,4,42397839-42402487,Predicted membrane proteins,Evidence at protein level,HPA054754,,,Approved,Lipid droplets<br>Cytosol,,Mixed,Tissue enhanced,,kidney: 25.1,lymph node: 8.7,Group enriched,6.0,AN3-CA: 231.0;PC-3: 134.3
124,SIM1,bHLHe14,ENSG00000112246,Single-minded family bHLH transcription factor 1,6,100385015-100464929,"Plasma proteins, Predicted intracellular proteins, Transcription factors",Evidence at transcript level,HPA024385,,,Approved,Nuclear speckles,Renal cancer:5.32e-7 (favourable),Tissue enhanced,Tissue enhanced,,epididymis: 3.5;kidney: 11.2;seminal vesicle: 3.2,skeletal muscle: 1.2,Cell line enhanced,,BJ: 13.9;BJ hTERT+: 19.3;RPTEC TERT1: 13.9
125,SIM2,"bHLHe15, MGC119447, SIM",ENSG00000159263,Single-minded family bHLH transcription factor 2,21,36699133-36749917,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA029295,Approved,,Supported,Nucleoplasm<br>Nuclear bodies,"Endometrial cancer:2.10e-4 (unfavourable), Urothelial cancer:2.88e-4 (favourable)",Tissue enhanced,Tissue enhanced,,esophagus: 22.8;kidney: 13.0;prostate: 10.3,stomach: 5.1,Cell line enhanced,,PC-3: 40.7;RPTEC TERT1: 41.3;RT4: 26.9
126,SLC14A2,"HUT2, UT2",ENSG00000132874,Solute carrier family 14 member 2,18,45212995-45683686,"Plasma proteins, Predicted membrane proteins, Transporters",Evidence at protein level,,,,,,,Tissue enhanced,Tissue enhanced,,kidney: 4.0,adipose tissue: 1.6,Cell line enriched,5.0,U-266/70: 3.4
127,SLC16A12,MCT12,ENSG00000152779,Solute carrier family 16 member 12,10,89430299-89556641,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at transcript level,HPA037587,,,Approved,Mitochondria,Renal cancer:4.50e-12 (favourable),Tissue enriched,Tissue enhanced,,epididymis: 63.5;kidney: 93.5,seminal vesicle: 20.2,Cell line enhanced,,ASC TERT1: 16.2;HSkMC: 6.0
128,SLC16A4,"MCT4, MCT5",ENSG00000168679,Solute carrier family 16 member 4,1,110362848-110391082,Predicted membrane proteins,Evidence at transcript level,"HPA046986, HPA060163",Approved,,Approved,Microtubules<br>Cytokinetic bridge<br>Cytosol,Renal cancer:1.69e-4 (favourable),Expressed in all,Tissue enhanced,,kidney: 125.2,placenta: 39.9,Cell line enhanced,,BEWO: 19.0;CAPAN-2: 26.1;SK-MEL-30: 24.1
129,SLC16A9,"C10orf36, FLJ43803, MCT9",ENSG00000165449,Solute carrier family 16 member 9,10,59650761-59736002,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA049286,Approved,,Approved,Nucleus<br>Cell Junctions,Renal cancer:2.56e-6 (favourable),Mixed,Tissue enhanced,,adrenal gland: 198.5;kidney: 201.0,spleen: 56.3,Cell line enhanced,,HAP1: 11.1;NTERA-2: 20.0;U-937: 14.6
130,SLC23A3,"FLJ31168, SVCT3, Yspl1",ENSG00000213901,Solute carrier family 23 member 3,2,219161465-219170095,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA019059,,,Approved,Nucleus<br>Cell Junctions,,Tissue enriched,Tissue enhanced,,kidney: 53.1;small intestine: 22.9,duodenum: 8.7,Cell line enhanced,,hTCEpi: 3.5
131,SLC25A48,"FLJ44862, HDMCP",ENSG00000145832,Solute carrier family 25 member 48,5,135834649-135888637,"Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,HPA014674,Uncertain,,Approved,Intermediate filaments<br>Actin filaments,,Mixed,Tissue enhanced,,cerebral cortex: 17.7;kidney: 7.3,skeletal muscle: 2.7,Cell line enhanced,,HAP1: 2.4;HEK93: 1.6;SCLC-21H: 2.0;U-2 OS: 2.3
132,SLC2A9,"Glut9, GLUTX, URATv1",ENSG00000109667,Solute carrier family 2 member 9,4,9771153-10054936,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,HPA066229,Enhanced,,,,Renal cancer:1.32e-11 (favourable),Mixed,Tissue enhanced,,kidney: 30.8;seminal vesicle: 27.2,placenta: 11.1,Cell line enhanced,,HBEC3-KT: 34.8;Hep G2: 16.1;hTCEpi: 14.4;THP-1: 13.9;U-937: 10.7
133,SLC30A2,ZNT2,ENSG00000158014,Solute carrier family 30 member 2,1,26037252-26046133,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,HPA017979,,,Approved,Vesicles,Renal cancer:2.86e-6 (favourable),Tissue enhanced,Tissue enhanced,,kidney: 22.0;thyroid gland: 42.4,pancreas: 16.5,Group enriched,5.0,BEWO: 2.4;RPTEC TERT1: 4.3;WM-115: 3.5
134,SLC37A4,"G6PT1, G6PT2, G6PT3, GSD1b, GSD1c, GSD1d",ENSG00000137700,Solute carrier family 37 member 4,11,119024114-119030906,Predicted membrane proteins,Evidence at protein level,"HPA038939, HPA038940",Enhanced,,Approved,Mitochondria,,Expressed in all,Tissue enhanced,,kidney: 36.6,duodenum: 30.8,Cell line enhanced,,HEK93: 24.3
135,SLC3A1,"ATR1, CSNU1, D2H, NBAT, RBAT",ENSG00000138079,Solute carrier family 3 member 1,2,44275458-44321494,"Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters",Evidence at protein level,"HPA038360, HPA071102",Enhanced,,Approved,Nuclear bodies<br>Mitochondria,Renal cancer:3.67e-7 (favourable),Tissue enriched,Tissue enhanced,,kidney: 688.2,small intestine: 148.9,Cell line enriched,14.0,RPTEC TERT1: 80.7
136,SLC47A1,"FLJ10847, MATE1",ENSG00000142494,Solute carrier family 47 member 1,17,19495385-19579034,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA021987,Enhanced,,,,"Endometrial cancer:5.54e-8 (favourable), Renal cancer:1.06e-5 (favourable), Lung cancer:1.88e-5 (favourable)",Tissue enhanced,Tissue enhanced,,adrenal gland: 138.3;kidney: 105.1,liver: 53.8,Cell line enhanced,,A549: 19.2;AN3-CA: 15.5;Hep G2: 28.2;U-266/70: 23.7
137,SLC4A4,"hhNMC, HNBC1, NBC1, NBC2, pNBC, SLC4A5",ENSG00000080493,Solute carrier family 4 member 4,4,71186757-71572087,"Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"CAB022493, HPA035628, HPA035629",Enhanced,,,,"Renal cancer:1.18e-4 (favourable), Colorectal cancer:7.69e-4 (favourable)",Group enriched,Tissue enhanced,,kidney: 125.8,cerebral cortex: 59.3,Cell line enhanced,,BJ: 12.5;RPTEC TERT1: 11.7;U-138 MG: 8.0
138,SLC5A12,"MGC52019, SMCT2",ENSG00000148942,Solute carrier family 5 member 12,11,26667019-26723427,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA060904,Enhanced,,,,,Tissue enriched,Tissue enhanced,,epididymis: 58.2;kidney: 173.7,small intestine: 33.4,Cell line enhanced,,Karpas-707: 1.6;NTERA-2: 1.7;T-47d: 1.1
139,SLC6A12,BGT-1,ENSG00000111181,Solute carrier family 6 member 12,12,190077-214570,"Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,HPA034973,Approved,,Approved,Vesicles,"Renal cancer:2.70e-6 (favourable), Endometrial cancer:1.59e-4 (unfavourable)",Tissue enhanced,Tissue enhanced,,kidney: 29.5;liver: 43.6,cerebral cortex: 14.8,Group enriched,10.0,Hep G2: 4.9;RPTEC TERT1: 10.5
140,SLC7A7,"LPI, y+LAT-1",ENSG00000155465,Solute carrier family 7 member 7,14,22773222-22829820,"Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,HPA036227,Enhanced,,,,Renal cancer:6.28e-6 (unfavourable),Expressed in all,Tissue enhanced,,kidney: 281.9,parathyroid gland: 162.5,Group enriched,5.0,BEWO: 191.5;CACO-2: 274.5;EFO-21: 65.6
141,SLCO4C1,"OATP-H, OATP4C1, OATPX, SLC21A20",ENSG00000173930,Solute carrier organic anion transporter family member 4C1,5,102233986-102296549,"Predicted membrane proteins, Transporters",Evidence at protein level,,,,,,Renal cancer:1.12e-4 (favourable),Tissue enriched,Tissue enhanced,,kidney: 42.4,lung: 11.2,Cell line enhanced,,Karpas-707: 12.0;RPTEC TERT1: 70.8;U-937: 19.1
142,SPP1,"BNSP, BSPI, ETA-1, OPN",ENSG00000118785,Secreted phosphoprotein 1,4,87975650-87983426,"Cancer-related genes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,"CAB002212, HPA027540, HPA027541",Enhanced,,Supported,Golgi apparatus,"Liver cancer:2.84e-6 (unfavourable), Pancreatic cancer:5.89e-4 (unfavourable), Cervical cancer:9.52e-4 (unfavourable)",Expressed in all,Tissue enhanced,,gallbladder: 3987.0;kidney: 2404.4;placenta: 4045.7,cerebral cortex: 795.2,Group enriched,6.0,EFO-21: 4669.3;Hep G2: 1742.5;RPTEC TERT1: 8242.5
143,STK32B,"HSA250839, STK32, STKG6, YANK2",ENSG00000152953,Serine/threonine kinase 32B,4,5051442-5500998,"Enzymes, Predicted intracellular proteins",Evidence at transcript level,HPA058536,,,Approved,Microtubules,Renal cancer:1.63e-8 (favourable),Mixed,Tissue enhanced,,kidney: 15.8,testis: 8.6,Cell line enhanced,,HUVEC TERT2: 22.9;REH: 22.7;U-2197: 40.5;WM-115: 110.5
144,SUCNR1,GPR91,ENSG00000198829,Succinate receptor 1,3,151873643-151884619,"G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,CAB022745,Uncertain,,,,,Mixed,Tissue enhanced,,kidney: 42.3,thyroid gland: 15.9,Group enriched,6.0,HEL: 47.7;NB-4: 19.6;U-937: 41.3
145,SUGCT,"C7orf10, DERP13, FLJ11808, ORF19",ENSG00000175600,Succinyl-CoA:glutarate-CoA transferase,7,40134977-40860763,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA026698, HPA026704, HPA026705",Enhanced,,,,"Renal cancer:3.93e-7 (favourable), Urothelial cancer:2.53e-4 (unfavourable)",Expressed in all,Tissue enhanced,,kidney: 45.0,liver: 14.6,Cell line enhanced,,HBEC3-KT: 30.6;LHCN-M2: 21.2
146,SULT1C2,"ST1C1, SULT1C1",ENSG00000198203,Sulfotransferase family 1C member 2,2,108288639-108309915,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA007190,Approved,,,,,Mixed,Tissue enhanced,,kidney: 69.0;stomach: 149.5,duodenum: 28.5,Cell line enhanced,,RPTEC TERT1: 19.5;RT4: 6.0
147,TCF24,bHLHa25,ENSG00000261787,Transcription factor 24,8,66946501-66962590,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Not detected,Tissue enhanced,,kidney: 1.2;testis: 2.8,fallopian tube: 0.7,Cell line enhanced,,HAP1: 2.2;HEK93: 5.0;HMC-1: 4.1
148,TFCP2L1,"CRTR1, LBP-9",ENSG00000115112,Transcription factor CP2 like 1,2,121216587-121285207,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA029708,Uncertain,,Supported,Nucleoli fibrillar center,Renal cancer:7.72e-6 (favourable),Mixed,Tissue enhanced,,kidney: 49.0,thyroid gland: 45.7,Cell line enhanced,,BEWO: 17.6;HEL: 14.0;hTCEpi: 12.5;RPTEC TERT1: 32.4;RT4: 25.3;SCLC-21H: 15.6
149,TLN2,"ILWEQ, KIAA0320",ENSG00000171914,Talin 2,15,62390526-62844631,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB017194, HPA051828, HPA054787",Enhanced,,Supported,Focal adhesion sites<br>Cytosol,"Renal cancer:1.81e-6 (favourable), Breast cancer:6.53e-4 (favourable), Stomach cancer:7.74e-4 (favourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 41.2;kidney: 41.1,thyroid gland: 21.7,Mixed,,
150,TMEM139,FLJ90586,ENSG00000178826,Transmembrane protein 139,7,143279957-143288048,"Predicted membrane proteins, Transporters",Evidence at protein level,"HPA036982, HPA036983",Approved,,Approved,Plasma membrane<br>Focal adhesion sites,"Renal cancer:3.05e-5 (favourable), Pancreatic cancer:1.66e-4 (unfavourable)",Mixed,Tissue enhanced,,duodenum: 34.0;kidney: 34.6,small intestine: 20.7,Cell line enhanced,,CAPAN-2: 35.7;EFO-21: 26.3;RPTEC TERT1: 53.2;T-47d: 64.1
151,TMEM252,"C9orf71, MGC34760",ENSG00000181778,Transmembrane protein 252,9,68536580-68540867,Predicted membrane proteins,Evidence at transcript level,,,,,,Renal cancer:1.75e-7 (favourable),Tissue enriched,Tissue enhanced,,kidney: 37.5;small intestine: 25.7,esophagus: 6.8,Cell line enhanced,,PC-3: 1.1;RPTEC TERT1: 1.8;SK-BR-3: 1.0
152,TMPRSS4-AS1,,ENSG00000255274,TMPRSS4 antisense RNA 1,11,118003634-118088299,Predicted membrane proteins,Evidence at transcript level,,,,,,,Not detected,Tissue enhanced,,kidney: 1.2,"lymph node,spleen: 0.8",Cell line enhanced,,Karpas-707: 7.8;RPMI-8226: 4.9;SCLC-21H: 1.7
153,TRABD2B,TIKI2,ENSG00000269113,TraB domain containing 2B,1,47760528-47996895,Predicted secreted proteins,Evidence at protein level,HPA045817,Approved,,,,,Tissue enriched,Tissue enhanced,,kidney: 7.7,seminal vesicle: 4.8,Group enriched,5.0,HeLa: 4.4;U-2197: 12.9
154,TRIM6,RNF89,ENSG00000121236,Tripartite motif containing 6,11,5596109-5612958,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA060514,Uncertain,,,,,Mixed,Tissue enhanced,,kidney: 22.5,testis: 17.2,Cell line enhanced,,NTERA-2: 22.2;U-2 OS: 22.5
155,TRPM3,"GON-2, KIAA1616, LTRPC3",ENSG00000083067,Transient receptor potential cation channel subfamily M member 3,9,70529063-71446904,"Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels",Evidence at protein level,,,,,,,Tissue enhanced,Tissue enhanced,,kidney: 17.6,testis: 5.6,Cell line enriched,5.0,HAP1: 17.8
156,UGT2A3,FLJ21934,ENSG00000135220,UDP glucuronosyltransferase family 2 member A3,4,68928463-68951791,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA045108,Supported,,,,"Renal cancer:6.07e-7 (favourable), Colorectal cancer:3.31e-4 (favourable)",Tissue enriched,Tissue enhanced,,duodenum: 82.1;gallbladder: 46.3;kidney: 46.8;small intestine: 85.9,rectum: 23.9,Cell line enriched,8.0,Hep G2: 13.5
157,UGT3A1,FLJ34658,ENSG00000145626,UDP glycosyltransferase family 3 member A1,5,35951010-36001028,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA047697, HPA056290",Uncertain,,Approved,Vesicles<br>Cytosol,,Group enriched,Tissue enhanced,,kidney: 53.4;liver: 29.2,duodenum: 9.5,Cell line enriched,51.0,RH-30: 26.5
158,VAV3,,ENSG00000134215,Vav guanine nucleotide exchange factor 3,1,107571160-107965144,Predicted intracellular proteins,Evidence at protein level,CAB002012,Uncertain,,,,Renal cancer:4.60e-8 (favourable),Expressed in all,Tissue enhanced,,kidney: 90.9,skin: 58.7,Cell line enhanced,,REH: 48.1;RH-30: 60.2;RPTEC TERT1: 66.0;T-47d: 100.9
159,VEPH1,"FLJ12604, KIAA1692",ENSG00000197415,Ventricular zone expressed PH domain containing 1,3,157259742-157533619,Predicted intracellular proteins,Evidence at protein level,HPA026645,Uncertain,,Approved,Nucleus<br>Nucleoli<br>Cytosol,Renal cancer:7.75e-9 (favourable),Mixed,Tissue enhanced,,adrenal gland: 26.6;kidney: 28.8;lung: 43.9,epididymis: 21.4,Cell line enhanced,,HUVEC TERT2: 204.2;TIME: 119.8
160,WNK4,PRKWNK4,ENSG00000126562,WNK lysine deficient protein kinase 4,17,42780678-42796936,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA016500,Approved,,,,,Mixed,Tissue enhanced,,kidney: 19.0;prostate: 15.4;rectum: 12.0,colon: 8.8,Cell line enhanced,,fHDF/TERT166: 26.2;K-562: 34.7;TIME: 29.5;WM-115: 23.9
